Showing results (361-370 of 404) with videos related to
Sort By:
Pageof 41
JAMA Oncology|March 3, 2022
Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical TrialXavier Pivot, M A Georgievich, Volodymyr Shamrai, et al.JAMA Oncology|February 14, 2020
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical TrialFausto Petrelli, Roberto Labianca, Alberto Zaniboni, et al.Clinical Breast Cancer|June 18, 2019
The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast CancerStefania Gori, Fabio Puglisi, Stefano Moroso, et al.International Journal of Cancer|June 9, 2022
Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trialAlessandra Raimondi, Giovanni Randon, Michele Prisciandaro, et al.European Journal of Cancer (Oxford, England : 1990)|December 13, 2016
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studiesMatteo Lambertini, Marcello Ceppi, Francesco Cognetti, et al.Frontiers in Oncology|December 7, 2020
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone MetastasesMarta Laganà, Cristina Gurizzan, Elisa Roca, et al.Pancreas|May 18, 2018
Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors: A Retrospective Multicenter AnalysisOronzo Brunetti, Giuseppe Aprile, Paolo Marchetti, et al.Lancet (London, England)|March 6, 2015
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trialLucia Del Mastro, Sabino De Placido, Paolo Bruzzi, et al.Journal of Thrombosis and Haemostasis : JTH|March 8, 2025
Activated factor XI-antithrombin and thrombin-antithrombin complexes in the prediction of venous thromboembolism and mortality in patients with non-small-cell lung cancerPatricia Gomez-Rosas, Magdolna Nagy, Henry M H Spronk, et al.Journal of Thrombosis and Haemostasis : JTH|April 13, 2023
Utility of the Khorana and the new-Vienna CATS prediction scores in cancer patients of the HYPERCAN cohortCristina Verzeroli, Cinzia Giaccherini, Laura Russo, et al.Pageof 41